Skip to content
Smartzyme Biopharma logo — company profile

Smartzyme Biopharma

Founded 2013 Israel Israel 2 employees Series B Total: $8.00M Biotechnology, Health Care +2

General Information

Company Name Smartzyme Biopharma
Founded Year 2013
Location Israel Israel
Employees 2
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Smartzyme Biopharma. To contact Smartzyme Biopharma, visit smzyme.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Smartzyme Biopharma compare?

A PDF of Smartzyme Biopharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Smartzyme Biopharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Smartzyme Biopharma

Smartzyme Biopharma is a biotechnology startup founded in 2013 and based in Israel. The company specializes in protein design and engineering using its proprietary technological platform, PROVOLUTION™. This platform combines advanced scientific tools for protein engineering, computational biology, and electrochemistry to create superior proteins and enzymes for various industrial applications. Led by CEO Shilo Ben Zeev and CTO David Baram, Ph.D., Smartzyme aims to address unmet needs in the industry by focusing on the Diabetes market. The company's first two products target the Self Monitoring Blood Glucose (SMBG) market, offering improved accuracy and stability compared to existing products. This includes a pre-designed enzyme for glucose test strips and the Go Patch Go™, a personalized patient care system for blood glucose measurement. In March 14, 2018, Smartzyme secured a Series B investment from OrbiMed and Virtus Inspire Ventures. The company's R&D efforts are further supported by a scientific advisory board comprised of leaders in protein engineering, structural biology, and electrochemistry. Smartzyme's innovative approach to protein design and engineering positions it as a promising player in the biopharma industry, with a focus on revolutionizing various industrial fields with its advanced technology.

Business keywords: Life Science, PROVOLUTION™, Protein Design, Enzyme Engineering, Medical Technology, Diabetes Management, Bio-Electrochemistry, Scientific Advisory Board, Biological Engineering, Industrial Innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed 2
OrbiMed, Virtus Inspire Ventures
14 Mar 2018
Seed Round $4.00M 1
OrbiMed
27 Oct 2015
Seed Round $4.00M -
04 Feb 2014

Smartzyme Biopharma Alternatives & Competitors

View All Alternatives
Smartzyme Biopharma vs

Our Mission: Make the Best Enzyme in the World.

Venture round
26 employees
Biotechnology, IT
Smartzyme Biopharma vs
Protein RST, LLC
Protein RST, LLC United States

English-Chinese scientific writing/translation, protein engineering, bio-medical lab supplies

0-1 employees
Biotechnology, Life Sciences
Smartzyme Biopharma vs
Biomatter
Biomatter Lithuania

Previously impossible enzymes for your visionary products

Seed
36 employees
Biopharma, Biotechnology

FAQ About Smartzyme Biopharma

SmartZyme is a life science company using PROVOLUTION™ , a proprietary technological platform for protein design and engineering, in accordance with industry required specifications. The company was founded in November 2013 by Shilo Ben Zeev (CEO) and David Baram, Ph.D. (CTO). The company aims...
Smartzyme Biopharma was founded in 2013.
Smartzyme Biopharma is headquartered in Israel.
Smartzyme Biopharma operates in Biotechnology, Health Care, Life Sciences and Manufacturing. Its work centres on Life Science, PROVOLUTION™, Protein Design and Enzyme Engineering.
Smartzyme Biopharma has approximately 2 employees.
Smartzyme Biopharma has completed 3 funding rounds, raising a total of $8.00M. The latest funding stage is Series B.
Top alternatives and competitors to Smartzyme Biopharma include Bestzyme, Protein RST, LLC, Biomatter, Arzeda, Fluidic Analytics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Smartzyme Biopharma and Bestzyme are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Smartzyme Biopharma, https://bouncewatch.com/company/smartzyme-biopharma, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout